Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
EGFRVIII expression + PTEN expression
Cancer:
Glioblastoma
Drug:
erlotinib
(
EGFR inhibitor
)
Direction:
Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
J Clin Oncol
Title:
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Excerpt:
For PFS...Both EGFRvIII expression and PTEN expression were present, but none had 6-month PFS or an objective response...
DOI:
10.1200/JCO.2008.17.5984
Trial ID:
NCT00086879
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login